Hims & Hers Q2 2026 Results: Guidance Raised
Hims & Hers Q2 2026 Results lifted full-year revenue and adjusted-EBITDA guidance after subscriber gains, sharpening trader focus on growth versus margins.
KEY TAKEAWAYS
- Raised full-year revenue to $3.1 billion-$3.3 billion and adjusted-EBITDA to $275 million-$325 million.
- Q2 revenue reached $753 million, up 38.0% year over year.
- Subscribers grew to 2.891 million, supporting the stronger outlook.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Hims & Hers Health, Inc. reported that rising subscribers and revenue led it on Aug. 10, 2026, to raise its full-year revenue and adjusted-EBITDA guidance, despite posting a second-quarter net loss that left profitability uneven.
Revenue Growth and Raised Guidance
The company said in a press release that its results covered the quarter ended June 30, 2026. Revenue reached $753.2 million, up 38.0% year over year, while subscribers increased 19.0% to 2.891 million. The top line exceeded analyst expectations, prompting management to raise full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion from a prior range of $2.8 billion to $3.0 billion. Adjusted EBITDA guidance was also lifted to $275 million to $325 million.
Profitability and Margin Pressure
Hims & Hers reported a net loss of $86.3 million for the quarter, while adjusted EBITDA was $60.3 million. Gross margin narrowed to 64.0% from 76.0% in the year-earlier quarter. Secondary reports attributed the stronger revenue and guidance increase to subscriber growth and expanded personalized healthcare offerings, including gains in international business. Shares declined on the mixed results.
The guidance upgrade reflects management’s confidence in sustaining revenue momentum, even as narrowing margins and the quarterly loss highlight the challenge of translating growth into consistent profitability.
